KAILASH MOSALPURIA M.D. MPH NPI 1669636643

NPI Details

Kailash Mosalpuria, M.D., MPH is a hematology and oncology internal medicine in Lincoln, NE with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Kailash Mosalpuria, M.D., MPH NPI is 1669636643. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4004 PIONEER WOODS DR
LINCOLN, NE
ZIP 68506
Phone: (402) 484-4900

The NPI 1669636643 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Uric acid level, blood (HCPCS:84550)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Ferritin (blood protein) level (HCPCS:82728)
• Red blood count, automated test (HCPCS:85045)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Chemical receptor analysis (HCPCS:84238)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Creatine kinase (cardiac enzyme) level, total (HCPCS:82550)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Magnesium level (HCPCS:83735)
• Vitamin d-3 level (HCPCS:82306)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Amylase (enzyme) level (HCPCS:82150)
• Folic acid level, serum (HCPCS:82746)
• Lipase (fat enzyme) level (HCPCS:83690)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Application of on-body injector for under skin injection (HCPCS:96377)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Injection of drug or substance into vein (HCPCS:96374)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of prolonged chemotherapy into vein (HCPCS:96416)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Erythropoietin (protein) level (HCPCS:82668)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)

The enumeration date for this NPI number is 7/18/2008 and was last updated on 5/1/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: